In this current study, we report that HSF1 upregulated PD-L1 expression by inducing APOJ expression and activating STAT3 signaling pathway in HCC, which will provide an experimental evidence for the possibility of making a precise strategy against cancer heterogeneity as well as improving immunotherapy efficacy in HCC. The gene discussed is CLU; the disease is hepatocellular carcinoma.